Related references
Note: Only part of the references are listed.Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Jesus F. San Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
M. A. Hurchla et al.
LEUKEMIA (2013)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2011)
Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma
Sung-Eun Lee et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
Michel Delforge et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
Maurizio Zangari et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
E. Terpos et al.
ANNALS OF ONCOLOGY (2010)
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro
Thomas Lund et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide
Monica De Matteo et al.
LEUKEMIA RESEARCH (2010)
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
Angela Pennisi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling
Ya-Wei Qiang et al.
BLOOD (2009)
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6
Huang Hongming et al.
LEUKEMIA RESEARCH (2009)
Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment
Orhan Sezer
ONCOLOGIST (2009)
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E. Terpos et al.
LEUKEMIA (2008)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I. Breitkreutz et al.
LEUKEMIA (2008)
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions
P. Boissy et al.
LEUKEMIA RESEARCH (2008)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Bortezomib inhibits osteoclast activity in patients with multiple myeloma
Geoffrey L. Uy et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
Stimulation of new bone formation by the proteasome inhibitor, bortezomib:: implications for myeloma bone disease
Babatunde O. Oyajobi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma
Shuji Ozaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Nicola Giuliani et al.
BLOOD (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Ulrike Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
M Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Myeloma bone disease: pathophysiology and management
E Terpos et al.
ANNALS OF ONCOLOGY (2005)
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function
I Zavrski et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants
JP Wu
AMERICAN JOURNAL OF TRANSPLANTATION (2002)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis
RZ Orlowski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)
Share Paper
